Canada's Medexus Pharmaceuticals Q1 revenue beats estimates
Overview
Medexus Pharmaceuticals fiscal Q1 2026 revenue of $24.6 mln beats analyst expectations
Adjusted EBITDA falls 44.3% to $3.4 mln, impacted by generic competition
GRAFAPEX generates $3.0 mln in revenue, expected to boost cash flows by fiscal Q3 2026
Outlook
Medexus expects GRAFAPEX revenue of $3.0 mln to $3.5 mln in fiscal Q2 2026
Company anticipates GRAFAPEX to be cash flow positive by fiscal Q3 2026
Medexus projects GRAFAPEX annual gross margin to reach 80%
Company does not expect EU tariffs to materially impact GRAFAPEX
Result Drivers
GRAFAPEX LAUNCH - Generated $3.0 mln in revenue, with positive market response and formulary inclusion supporting its potential
GENERIC COMPETITION - Decline in revenue and adjusted EBITDA attributed to generic competition affecting products like Rupall
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Beat | $24.60 mln | $24.50 mln (4 Analysts) |
Q1 Net Income |
| $500,000 |
|
Q1 Adjusted EBITDA |
| $3.40 mln |
|
Q1 Operating Income |
| $900,000 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Medexus Pharmaceuticals Inc is C$6.00, about 54.2% above its August 12 closing price of C$2.75
Press Release: ID:nNFC8Gxh3D
Related Articles
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing..jpg)
Crypto Stocks Ignite ARKK’s Q2 NAV Surge of 46.96%
ARK Innovation ETF (ARKK), managed by Cathie Wood, delivered a stellar performance in Q2 2025, with its net asset value (NAV) soaring by 46.96%, reaffirming Wood’s reputation as one of Wall Street’s most polarizing yet influential fund managers.
U.S. July CPI Commentary: Obstacles Cleared, Where Will U.S. Stocks Go Next?
TradingKey - On 12 August 2025, the United States released its Consumer Price Index (CPI) data for July. In terms of headline inflation, the CPI rose by 2.7% year-on-year in the month, slightly lower than the expected 2.8%. However, core CPI climbed 3.1% year-on-year, edging past the projected 3.0%.
.jpg)
